Table of Contents_x000D_
List of Tables_x000D_
List of Figures_x000D_
1 Introduction_x000D_
1.1 What Is This Report About?_x000D_
1.2 Hormonal Disorders Market Segmentation_x000D_
1.3 Definitions of Markets Covered in the Report_x000D_
2 Hormonal Disorders Market, North America_x000D_
2.1 Hormonal Disorders Market, North America, Revenue ($m), 2024-2036_x000D_
2.2 Hormonal Disorders Market, North America, Revenue ($m), 2024-2036_x000D_
2.3 Hormonal Disorders Market, North America, Volume (Units), 2024-2036_x000D_
2.4 Hormonal Disorders Market, North America, Volume (Units), 2024-2036_x000D_
2.5 Hormonal Disorders Market, North America, Company Share by Revenue ($m), 2025_x000D_
3 Hormonal Disorders Market, Canada_x000D_
3.1 Hormonal Disorders Market, Canada, Revenue ($m), 2024-2036_x000D_
3.1.1 Thyroid Function Tests Market, Canada, Revenue ($m), by Segment, 2024-2036_x000D_
3.2 Hormonal Disorders Market, Canada, Volume (Units), 2024-2036_x000D_
3.2.1 Thyroid Function Tests Market, Canada, Volume (Units), by Segment, 2024-2036_x000D_
3.3 Hormonal Disorders Market, Canada, Average Price ($), 2024-2036_x000D_
3.4 Hormonal Disorders Market, Canada, Company Share by Revenue ($m), 2025_x000D_
4 Hormonal Disorders Market, Mexico_x000D_
4.1 Hormonal Disorders Market, Mexico, Revenue ($m), 2024-2036_x000D_
4.1.1 Thyroid Function Tests Market, Mexico, Revenue ($m), by Segment, 2024-2036_x000D_
4.2 Hormonal Disorders Market, Mexico, Volume (Units), 2024-2036_x000D_
4.2.1 Thyroid Function Tests Market, Mexico, Volume (Units), by Segment, 2024-2036_x000D_
4.3 Hormonal Disorders Market, Mexico, Average Price ($), 2024-2036_x000D_
4.4 Hormonal Disorders Market, Mexico, Company Share by Revenue ($m), 2025_x000D_
5 Hormonal Disorders Market, United States_x000D_
5.1 Hormonal Disorders Market, United States, Revenue ($m), 2024-2036_x000D_
5.1.1 Thyroid Function Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_
5.2 Hormonal Disorders Market, United States, Volume (Units), 2024-2036_x000D_
5.2.1 Thyroid Function Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_
5.3 Hormonal Disorders Market, United States, Average Price ($), 2024-2036_x000D_
5.4 Hormonal Disorders Market, United States, Company Share by Revenue ($m), 2025_x000D_
6 Hormonal Disorders Market Pipeline Products_x000D_
6.1 Hormonal Disorders Market Pipeline Products_x000D_
6.2 Hormonal Disorders – Pipeline Products by Stage of Development_x000D_
6.3 Hormonal Disorders – Pipeline Products by Segment_x000D_
6.4 Hormonal Disorders – Pipeline Products by Territory_x000D_
6.5 Hormonal Disorders – Pipeline Products by Regulatory Path_x000D_
6.6 Hormonal Disorders – Pipeline Products by Estimated Approval Date_x000D_
7 Overview of Key Companies in North America Hormonal Disorders Market_x000D_
7.1 Siemens Healthineers AG_x000D_
7.1.1 Company Overview_x000D_
7.2 Beckman Coulter Inc_x000D_
7.2.1 Company Overview_x000D_
7.3 Roche Diagnostics International Ltd_x000D_
7.3.1 Company Overview_x000D_
7.4 Abbott Laboratories_x000D_
7.4.1 Company Overview_x000D_
7.5 Ortho Clinical Diagnostics Holdings Ltd (Inactive)_x000D_
7.5.1 Company Overview_x000D_
7.6 Inova Diagnostics Inc_x000D_
7.6.1 Company Overview_x000D_
8 Recent Developments_x000D_
8.1 Corporate Communications_x000D_
8.1.1 Nov 17, 2025: Fortrea Appoints Agnieszka Gallagher as General Counsel_x000D_
8.1.2 Nov 14, 2025: COSCIENS Biopharma Announces Leadership Change_x000D_
8.1.3 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
8.1.4 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager_x000D_
8.1.5 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
8.1.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
8.1.7 Oct 13, 2025: EASL CPGs Dissemination And Implementation Programme_x000D_
8.1.8 Oct 09, 2025: Abbott And Abbott Fund Support Northern Illinois Food Bank With $250,000 Grant To Address Childhood Hunger_x000D_
8.2 Financial Announcements_x000D_
8.2.1 Mar 25, 2026: COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update_x000D_
8.2.2 Jan 05, 2026: Abbott Hosts Conference Call for Fourth-Quarter Earnings_x000D_
8.2.3 Nov 11, 2025: COSCIENS Biopharma Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update_x000D_
8.3 Government and Public Interest_x000D_
8.3.1 Nov 25, 2025: Fortrea to Present at Citi and Evercore Healthcare Conferences_x000D_
8.4 Other Significant Developments_x000D_
8.4.1 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
8.4.2 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
8.5 Product News_x000D_
8.5.1 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV_x000D_
8.5.2 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
8.5.3 Jul 16, 2025: Multicenter Trial Confirms Near-Infrared Autofluorescence Increases Detection of Parathyroid Glands_x000D_
8.6 Strategy And Business Planning_x000D_
8.6.1 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
8.6.2 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics_x000D_
8.6.3 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics_x000D_
8.6.4 Oct 28, 2025: Tanenbaum Institute for Science in Sport and Saint-Étienne University Hospital Collaborate on Sport and Health Research_x000D_
9 Appendix_x000D_
9.1 Research Methodology_x000D_
9.1.1 Coverage_x000D_
9.1.2 Secondary Research_x000D_
9.1.3 Primary Research_x000D_
9.1.4 Market Modeling and Forecasting_x000D_
9.1.5 Company Share Analysis_x000D_
9.1.6 Benchmarking_x000D_
9.2 GlobalData Consulting_x000D_
9.3 Contact Us_x000D_
9.4 Disclaimer